Tag: IR

AB „Ignitis grupė“ (toliau – Grupė) informuoja, kad birželio 30 d., gavus Grupės valdybos patvirtinimą, Grupės dukterinės įmonės UAB „Ignitis renewables“ (toliau – „Ignitis renewables“) ir AB „Ignitis gamyba“ (toliau – „Ignitis gamyba“) priėmė galutinius investicinius sprendimus dėl trijų elektros energijos kaupiklių sistemų (toliau – EEKS) projektų Lietuvoje, kurių bendra galia siekia 291 MW, o talpa – 582 MWh. Vokietijos bendrovė Rolls-Royce Solutions GmbH yra pasirinkta dėl įrangos tiekimo ir jos integravimo visiems trims projektams.

Palo Alto, California, June 30, 2025 (GLOBE NEWSWIRE) --  NMP Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 10,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right. Each right entitles the holder to receive one-fifth (1/5) of one Class A ordinary share upon consummation of the Company’s initial business combination. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust Company acting as trustee. Up to $300,000 of interest earned on the funds held in the trust account, in the aggregate, may be released to us to fund our working capital requirements.  In addition, we may withdraw interest earned on the trust to pay our income and franchise taxes, if any. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “NMPAU” beginning on July 1, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to trade on Nasdaq under the symbols “NMP” and “NMPAR,” respectively.

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio

BEIJING, June 30, 2025 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the “Company” or “TRX”), a China-based insurance broker, today announced it has completed the acquisition of 100% of issued and outstanding shares of Ucare Inc. (“Ucare”), the sole operator of China’s only cloud-based AI-driven hospital and health insurance risk management platform. The all-stock transaction, valued at US$150 million, marks a major milestone in TRX’s strategy to expand into in-hospital distribution channels and capture new growth opportunities within the health insurance sector.

KPN has repurchased 1,675,000 KPN ordinary shares in the period from 23 June to 27 June 2025. The shares were repurchased at an average price of € 4.15 per share for a total consideration of € 7.0m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders.

DALIAN, China, June 30, 2025 (GLOBE NEWSWIRE) -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy" or the "Company"), a leading manufacturer of lithium-ion and sodium-ion batteries and comprehensive electric energy solutions in China, today announced that its wholly-owned subsidiary, China BAK Asia Holdings Limited ("China BAK"), has entered into a significant strategic partnership (the “Partnership”) with Anker Innovations Technology Co., Ltd. (Shenzhen Stock Exchange: 300866, “Anker Innovations”), a global leader in intelligent hardware and one of CBAK Energy’s largest customers. As part of this Partnership, CBAK Energy will establish a new battery cell manufacturing facility in Malaysia (the “Malaysian Project”), with construction beginning immediately. The facility is expected to commence mass production of the Company’s flagship LFP cylindrical battery models, 32140 and 40135, by the end of 2025.

CEO Emil Malak Discusses VoIP-Pal’s Legal Strategy and Market Vision in New CEOCFO Interview — Read the Full Q&A here

30 June 2025

SHANGHAI, China, June 30, 2025 (GLOBE NEWSWIRE) -- Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qifu Technology” or the “Company”), a leading AI-empowered Credit-Tech platform in China, today announced that the following proposed resolutions submitted for shareholder approval have been duly adopted at its annual general meeting of shareholders held today:

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —